Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: A blood and marrow transplant clinical trials network study

John E. Levine, Brent R. Logan, Juan Wu, Amin M. Alousi, Javier Bolaños-Meade, James L M Ferrara, Vincent T. Ho, Daniel J. Weisdorf, Sophie Paczesny

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Acute graft-versus-host disease (GVHD) is the primary limitation of allogeneic hematopoietic cell transplantation, and once it develops, there are no reliable diagnostic tests to predict treatment outcomes. We hypothesized that 6 previously validated diagnostic biomarkers of GVHD (IL-2 receptor-α; tumor necrosis factor receptor-1; hepatocyte growth factor; IL-8; elafin, a skin-specific marker; and regenerating islet-derived 3-α, a gastrointestinal tract-specific marker) could discriminate between therapy responsive and nonresponsive patients and predict survival in patients receiving GVHD therapy. We measured GVHD biomarker concentrations from samples prospectively obtained at the initiation of treatment, day 14, and day 28, on a multi-center, randomized, 4-arm phase 2 clinical trial for newly diagnosed acute GVHD. We found that at each of 3 time points, GVHD onset, 2 weeks into treatment, and 4 weeks into treatment, a 6-protein biomarker panel predicted for the important clinical outcomes of day 28 posttherapy nonresponse and mortality at day 180 from onset. GVHD biomarker panels can be used for early identification of patients at high or low risk for treatment nonrespon-siveness or death, and they may provide opportunities for early intervention and improved survival after hematopoietic cell transplantation. The study was registered in clinicaltrials.gov as NCT00224874.

Original languageEnglish (US)
Pages (from-to)3854-3860
Number of pages7
JournalBlood
Volume119
Issue number16
DOIs
StatePublished - Apr 19 2012
Externally publishedYes

Fingerprint

Transplants
Biomarkers
Graft vs Host Disease
Grafts
Blood
Bone Marrow
Clinical Trials
Cell Transplantation
Therapeutics
Elafin
Hepatocyte Growth Factor
Survival
Tumor Necrosis Factor Receptors
Interleukin-2 Receptors
Interleukin-8
Routine Diagnostic Tests
Gastrointestinal Tract
Skin
Arm
Mortality

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes : A blood and marrow transplant clinical trials network study. / Levine, John E.; Logan, Brent R.; Wu, Juan; Alousi, Amin M.; Bolaños-Meade, Javier; Ferrara, James L M; Ho, Vincent T.; Weisdorf, Daniel J.; Paczesny, Sophie.

In: Blood, Vol. 119, No. 16, 19.04.2012, p. 3854-3860.

Research output: Contribution to journalArticle

Levine, John E. ; Logan, Brent R. ; Wu, Juan ; Alousi, Amin M. ; Bolaños-Meade, Javier ; Ferrara, James L M ; Ho, Vincent T. ; Weisdorf, Daniel J. ; Paczesny, Sophie. / Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes : A blood and marrow transplant clinical trials network study. In: Blood. 2012 ; Vol. 119, No. 16. pp. 3854-3860.
@article{fa1d3f1fc81442f8a736fde22e77bf31,
title = "Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: A blood and marrow transplant clinical trials network study",
abstract = "Acute graft-versus-host disease (GVHD) is the primary limitation of allogeneic hematopoietic cell transplantation, and once it develops, there are no reliable diagnostic tests to predict treatment outcomes. We hypothesized that 6 previously validated diagnostic biomarkers of GVHD (IL-2 receptor-α; tumor necrosis factor receptor-1; hepatocyte growth factor; IL-8; elafin, a skin-specific marker; and regenerating islet-derived 3-α, a gastrointestinal tract-specific marker) could discriminate between therapy responsive and nonresponsive patients and predict survival in patients receiving GVHD therapy. We measured GVHD biomarker concentrations from samples prospectively obtained at the initiation of treatment, day 14, and day 28, on a multi-center, randomized, 4-arm phase 2 clinical trial for newly diagnosed acute GVHD. We found that at each of 3 time points, GVHD onset, 2 weeks into treatment, and 4 weeks into treatment, a 6-protein biomarker panel predicted for the important clinical outcomes of day 28 posttherapy nonresponse and mortality at day 180 from onset. GVHD biomarker panels can be used for early identification of patients at high or low risk for treatment nonrespon-siveness or death, and they may provide opportunities for early intervention and improved survival after hematopoietic cell transplantation. The study was registered in clinicaltrials.gov as NCT00224874.",
author = "Levine, {John E.} and Logan, {Brent R.} and Juan Wu and Alousi, {Amin M.} and Javier Bola{\~n}os-Meade and Ferrara, {James L M} and Ho, {Vincent T.} and Weisdorf, {Daniel J.} and Sophie Paczesny",
year = "2012",
month = "4",
day = "19",
doi = "10.1182/blood-2012-01-403063",
language = "English (US)",
volume = "119",
pages = "3854--3860",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "16",

}

TY - JOUR

T1 - Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes

T2 - A blood and marrow transplant clinical trials network study

AU - Levine, John E.

AU - Logan, Brent R.

AU - Wu, Juan

AU - Alousi, Amin M.

AU - Bolaños-Meade, Javier

AU - Ferrara, James L M

AU - Ho, Vincent T.

AU - Weisdorf, Daniel J.

AU - Paczesny, Sophie

PY - 2012/4/19

Y1 - 2012/4/19

N2 - Acute graft-versus-host disease (GVHD) is the primary limitation of allogeneic hematopoietic cell transplantation, and once it develops, there are no reliable diagnostic tests to predict treatment outcomes. We hypothesized that 6 previously validated diagnostic biomarkers of GVHD (IL-2 receptor-α; tumor necrosis factor receptor-1; hepatocyte growth factor; IL-8; elafin, a skin-specific marker; and regenerating islet-derived 3-α, a gastrointestinal tract-specific marker) could discriminate between therapy responsive and nonresponsive patients and predict survival in patients receiving GVHD therapy. We measured GVHD biomarker concentrations from samples prospectively obtained at the initiation of treatment, day 14, and day 28, on a multi-center, randomized, 4-arm phase 2 clinical trial for newly diagnosed acute GVHD. We found that at each of 3 time points, GVHD onset, 2 weeks into treatment, and 4 weeks into treatment, a 6-protein biomarker panel predicted for the important clinical outcomes of day 28 posttherapy nonresponse and mortality at day 180 from onset. GVHD biomarker panels can be used for early identification of patients at high or low risk for treatment nonrespon-siveness or death, and they may provide opportunities for early intervention and improved survival after hematopoietic cell transplantation. The study was registered in clinicaltrials.gov as NCT00224874.

AB - Acute graft-versus-host disease (GVHD) is the primary limitation of allogeneic hematopoietic cell transplantation, and once it develops, there are no reliable diagnostic tests to predict treatment outcomes. We hypothesized that 6 previously validated diagnostic biomarkers of GVHD (IL-2 receptor-α; tumor necrosis factor receptor-1; hepatocyte growth factor; IL-8; elafin, a skin-specific marker; and regenerating islet-derived 3-α, a gastrointestinal tract-specific marker) could discriminate between therapy responsive and nonresponsive patients and predict survival in patients receiving GVHD therapy. We measured GVHD biomarker concentrations from samples prospectively obtained at the initiation of treatment, day 14, and day 28, on a multi-center, randomized, 4-arm phase 2 clinical trial for newly diagnosed acute GVHD. We found that at each of 3 time points, GVHD onset, 2 weeks into treatment, and 4 weeks into treatment, a 6-protein biomarker panel predicted for the important clinical outcomes of day 28 posttherapy nonresponse and mortality at day 180 from onset. GVHD biomarker panels can be used for early identification of patients at high or low risk for treatment nonrespon-siveness or death, and they may provide opportunities for early intervention and improved survival after hematopoietic cell transplantation. The study was registered in clinicaltrials.gov as NCT00224874.

UR - http://www.scopus.com/inward/record.url?scp=84860345135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860345135&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-01-403063

DO - 10.1182/blood-2012-01-403063

M3 - Article

C2 - 22383800

AN - SCOPUS:84860345135

VL - 119

SP - 3854

EP - 3860

JO - Blood

JF - Blood

SN - 0006-4971

IS - 16

ER -